受体
2型糖尿病
生物
医学
药理学
糖尿病
内科学
内分泌学
作者
Giulia Bendotti,Laura Montefusco,Maria Elena Lunati,Vera Usuelli,Ida Pastore,Elisa Lazzaroni,Emma Assi,Andy Joe Seelam,Basset El Essawy,Jun Young Jang,Cristian Loretelli,Francesca D’Addio,Cesare Berra,Moufida Ben Nasr,Gian Vincenzo Zuccotti,Paolo Fiorina
标识
DOI:10.1016/j.phrs.2022.106320
摘要
In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested that GLP-1RAs have anti-inflammatory properties and that may modulate the immune-system. Notably, such anti-inflammatory effects target different pathways in different tissues, underling the broad spectrum of GLP-1RAs actions. This review examines some of the currently proposed molecular mechanisms of GLP-1RAs actions and explores their potential benefits in reducing inflammatory responses, which may well suggest a future therapeutic use of GLP-1RAs in new indications.
科研通智能强力驱动
Strongly Powered by AbleSci AI